… ) to be conducted to test whether vaccination with the pneumococcal polysaccharide vaccine
will reduce cardiovascular events. If successful, vaccination can be readily extended to at-…

… in children vaccinated with type b polysaccharide vaccine. N … b polysaccharide-outer
membrane protein conjugate vaccine … previous vaccination with type b polysaccharide vaccine. J …

… Here we describe the rationale and design behind the … Vi polysaccharide (PS) vaccine
and present preliminary results of the pilot phase that guided decisions in the final study design …

… Although the 23-valent polysaccharide pneumococcal vaccine (23vPs) is considered
effective in the prevention of invasive pneumococcal disease in the elderly population, the …

… of the failure of many to perceive that the aggregate efficacy ef a vaccine designed to
prevent 23 immunologieally distinct infections is unlikely ever to equal that of a monovalent …

… polysaccharides, and this led to the formulation of a 23-valent polysaccharide vaccine which
remains the current vaccine … of the polysaccharides used in the current vaccine are shown …

… The liposomes have been designed in some applications to contain and deliver vaccine …
antigen-specific B lymphocytes a means to bind the polysaccharide via their antibody and …

… Such vaccines were based on the use of capsular polysaccharide (CPS) preparations …
underlying polysaccharide vaccine-induced immunity. However, plain polysaccharide vaccines …

… For example, the meningococcal unconjugated polysaccharide vaccine given in young
children leads to a significant ELISA-detectable antibody binding response but provides poor …

… A promising area of research to overcome the deficiency of polysaccharide vaccines in
infants is the design of a new generation of semisynthetic vaccines based on the conjugation (…